New CT scanner aims to spot tiny, dangerous lung clots
NCT ID NCT07575503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new type of CT scanner (photon-counting CT) with standard CT to see if it can better detect very small blood clots in the lungs, called subsegmental pulmonary embolism. About 696 adults with suspected acute pulmonary embolism will be scanned with both methods. The goal is to improve diagnosis and guide treatment for these hard-to-find clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 696 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults (≥18 years) presenting with clinical symptoms and signs suggestive of acute pulmonary embolism will be enrolled. Eligible patients are those with a simplified revised Geneva score ≥3 and abnormal findings on electrocardiogram, echocardiography, or pulse oximetry, which support the suspicion of pulmonary embolism. Patients will be prospectively recruited from the emergency department and inpatient wards of the Second Affiliated Hospital, Zhejiang University School of Medicine. The study population is representative of patients with suspected acute pulmonary embolism who require CT pulmonary angiography for diagnostic confirmation.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 18 years 2. Clinical manifestations supporting the diagnosis of acute pulmonary embolism, including: Acute onset or progressive dyspnea Unexplained hypoxemia Chest pain Hemoptysis Syncope or presyncope Combined with abnormal findings on electrocardiogram, echocardiography, or pulse oximetry 3. Revised simplified Geneva score ≥ 3 4. Written informed consent obtained from the patient or the patient's legally authorized representative Exclusion Criteria: 1. Patients requiring prophylactic or therapeutic doses of anticoagulant medication for reasons other than venous thromboembolism (VTE). 2. Life expectancy less than three months. 3. Patients unable to undergo CT scanning due to severe condition or hemodynamic instability. 4. History of allergy to contrast media, renal insufficiency (creatinine clearance \< 30 mL/min), or ongoing long-term dialysis. 5. Pregnancy. 6. Refusal to provide informed consent or inability to complete follow-up for any reason.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Photon-counting computed tomography are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.